Because there are a variety of TLRs and associated pathogen associated molecular patterns (PAMPs), like flagellin and TLR5 (27), TLR agonists could provide customization towards the bacteria in use and corresponding desired anti-tumor response. The gene discussed is TLR5; the disease is neoplasm.